125 related articles for article (PubMed ID: 38691205)
1. Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.
Liu S; Li Y; Li Z; Wu S; Harrold JM; Shah DK
J Pharmacokinet Pharmacodyn; 2024 May; ():. PubMed ID: 38691205
[TBL] [Abstract][Full Text] [Related]
2. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
Li Z; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
[TBL] [Abstract][Full Text] [Related]
3. Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.
Sepp A; Meno-Tetang G; Weber A; Sanderson A; Schon O; Berges A
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):339-359. PubMed ID: 31079322
[TBL] [Abstract][Full Text] [Related]
4. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
6. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
Chang HY; Wu S; Chowdhury EA; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans.
Jagdale P; Sepp A; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):607-624. PubMed ID: 36266517
[TBL] [Abstract][Full Text] [Related]
8. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.
Patidar K; Pillai N; Dhakal S; Avery LB; Mavroudis PD
J Pharmacokinet Pharmacodyn; 2024 Feb; ():. PubMed ID: 38400996
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.
Wong H; Chow TW
J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453
[TBL] [Abstract][Full Text] [Related]
10. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice.
Li Z; Li Y; Chang HP; Yu X; Shah DK
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):743-762. PubMed ID: 34146191
[TBL] [Abstract][Full Text] [Related]
11. A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments.
Li Z; Yu X; Li Y; Verma A; Chang HP; Shah DK
AAPS J; 2021 May; 23(3):62. PubMed ID: 33942169
[TBL] [Abstract][Full Text] [Related]
12. Effect of Size on Solid Tumor Disposition of Protein Therapeutics.
Li Z; Li Y; Chang HP; Chang HY; Guo L; Shah DK
Drug Metab Dispos; 2019 Oct; 47(10):1136-1145. PubMed ID: 31387870
[TBL] [Abstract][Full Text] [Related]
13. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
Khot A; Tibbitts J; Rock D; Shah DK
AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
[TBL] [Abstract][Full Text] [Related]
14. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.
Chen Y; Balthasar JP
AAPS J; 2012 Dec; 14(4):850-9. PubMed ID: 22956476
[TBL] [Abstract][Full Text] [Related]
16. PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.
Wu S; Le Prieult F; Phipps CJ; Mezler M; Shah DK
J Pharmacokinet Pharmacodyn; 2022 Dec; 49(6):579-592. PubMed ID: 36088452
[TBL] [Abstract][Full Text] [Related]
17. A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs.
Davda JP; Jain M; Batra SK; Gwilt PR; Robinson DH
Int Immunopharmacol; 2008 Mar; 8(3):401-13. PubMed ID: 18279794
[TBL] [Abstract][Full Text] [Related]
18. Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.
Sepp A; Bergström M; Davies M
MAbs; 2020; 12(1):1832861. PubMed ID: 33073698
[TBL] [Abstract][Full Text] [Related]
19. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
Niederalt C; Kuepfer L; Solodenko J; Eissing T; Siegmund HU; Block M; Willmann S; Lippert J
J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):235-257. PubMed ID: 29234936
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies.
Liu S; Shah DK
AAPS J; 2023 Apr; 25(3):48. PubMed ID: 37118220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
